[go: up one dir, main page]

AU2001231917A1 - Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein - Google Patents

Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein

Info

Publication number
AU2001231917A1
AU2001231917A1 AU2001231917A AU3191701A AU2001231917A1 AU 2001231917 A1 AU2001231917 A1 AU 2001231917A1 AU 2001231917 A AU2001231917 A AU 2001231917A AU 3191701 A AU3191701 A AU 3191701A AU 2001231917 A1 AU2001231917 A1 AU 2001231917A1
Authority
AU
Australia
Prior art keywords
protein
scntfralpha
nnt
clf
addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231917A
Inventor
Sylvie Chevalier
Greg Elson
Hugues Gascan
Jean-Francois Gauchat
Helene Plun-Favreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Pierre Fabre Medicament SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0001035A external-priority patent/FR2804434A1/en
Application filed by Pierre Fabre Medicament SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Pierre Fabre Medicament SA
Publication of AU2001231917A1 publication Critical patent/AU2001231917A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001231917A 2000-01-27 2001-01-26 Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein Abandoned AU2001231917A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0001035 2000-01-27
FR0001035A FR2804434A1 (en) 2000-01-27 2000-01-27 A complex comprising a NNT-1 protein and a CLF-1 and/or sCNTFRalpha protein useful to treat neurodegenerative disease including Parkinson's and Huntington's, obesity and cancer
FR0013089 2000-10-12
FR0013089A FR2804435A1 (en) 2000-01-27 2000-10-12 ISOLATED COMPLEX COMPRISING AN NNT-1 PROTEIN AND FURTHER AT LEAST ONE CLF-1 PROTEIN AND / OR A sCNTFRalpha PROTEIN
PCT/FR2001/000253 WO2001055172A2 (en) 2000-01-27 2001-01-26 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN

Publications (1)

Publication Number Publication Date
AU2001231917A1 true AU2001231917A1 (en) 2001-08-07

Family

ID=26212128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231917A Abandoned AU2001231917A1 (en) 2000-01-27 2001-01-26 Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein

Country Status (3)

Country Link
AU (1) AU2001231917A1 (en)
FR (1) FR2804435A1 (en)
WO (1) WO2001055172A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003500010A (en) * 1999-03-11 2003-01-07 シェリング・コーポレーション Mammalian cytokines; related reagents and methods
EP3436078B1 (en) * 2016-03-31 2021-10-27 University of Cincinnati Methods and compositions for the treatment of als
US20200297868A1 (en) * 2016-12-14 2020-09-24 University Of Cincinnati Methods and compositions for the treatment of als

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226097T3 (en) * 1997-02-03 2005-03-16 Amgen Inc. NNT-1 NEUROTROPHIC FACTOR.
WO1999000415A1 (en) * 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cardiotrophin-like cytokine
WO1999035264A1 (en) * 1998-01-09 1999-07-15 Immunex Corporation H14 dna and polypeptides
AU2661199A (en) * 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
JP2003500010A (en) * 1999-03-11 2003-01-07 シェリング・コーポレーション Mammalian cytokines; related reagents and methods

Also Published As

Publication number Publication date
WO2001055172A2 (en) 2001-08-02
WO2001055172A3 (en) 2001-11-15
FR2804435A1 (en) 2001-08-03

Similar Documents

Publication Publication Date Title
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002243246A1 (en) Cddo-compounds and combination therapies thereof
AU6058500A (en) Fusion protein and uses thereof
AU2002246502A1 (en) Nucleic acids and polypeptides
AU2001236726A1 (en) Protein separation and display
AU2002211717A1 (en) Stresscopins and their uses
AU5340399A (en) Proteases and associated proteins
AU2001292561A1 (en) Nucleic acids and polypeptides
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU4776800A (en) Acetylcholinesterase-derived peptides and uses thereof
AU2001274566A1 (en) Novel protein and dna thereof
EP1302770A4 (en) Particle-labeled protein and immuno-chromatograph using the same
AU2001272655A1 (en) Improvements in valves
AU2001231917A1 (en) Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AU2002256556A1 (en) Sea-trosy and related methods
AU2001280993A1 (en) Tissue-associated proteins and their uses
AU2001252921A1 (en) A glycopeptide and preparation thereof
AU2001277519A1 (en) Bio-probes and use thereof
AU2001256977A1 (en) Human sez6 nucleic acids and polypeptides
AU2001288544A1 (en) 52991, a human transporter protein and uses therefor
AU2001294267A1 (en) Survivin-like polypeptides and dnas thereof
AU2001274563A1 (en) Novel polypeptide and its dna